B of A Securities Downgrades NeoGenomics to Neutral, Lowers Price Target to $18
B of A Securities downgrades NeoGenomics (NASDAQ:NEO) from Buy to Neutral and lowers the price target from $25 to $18.
Where NeoGenomics Stands With Analysts
Over the past 3 months, 8 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $28
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $35 to $28.
Stephens & Co. Downgrades NeoGenomics to Equal-Weight, Lowers Price Target to $16
Stephens & Co. downgrades NeoGenomics (NASDAQ:NEO) from Overweight to Equal-Weight and lowers the price target from $34 to $16.
SVB Leerink Maintains Outperform on NeoGenomics, Lowers Price Target to $20
SVB Leerink analyst Puneet Souda maintains NeoGenomics (NASDAQ:NEO) with a Outperform and lowers the price target from $45 to $20.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
NexImmune (NASDAQ:NEXI) stock moved upwards by 8.3% to $3.51 during Monday's after-market session. This security traded at a volume of 109.1K shares come close, making up 76.6% of its average volume over the last 100 days. The company's market cap stands at $80.1 million.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Want To Buy Crypto? Check Out The Top Movers For Today
According to Benzinga Pro, the following are the crypto gainers and losers at the time of publication:
10 Biggest Price Target Changes For Thursday
SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading.
Needham Maintains Buy on NeoGenomics, Lowers Price Target to $29
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $41 to $29.